ASML’s rise to a roughly $670 billion market value makes it Europe’s most valuable listed company and underscores how the continent’s biggest equity story is now tied to advanced chipmaking rather than banks or consumer brands.
ASML Becomes Europe’s Most Valuable Listed Company
That matters because ASML sits at the center of the global semiconductor supply chain as the only supplier of extreme ultraviolet lithography systems, the machines needed to make the most advanced chips used in AI accelerators, smartphones and data centers. Its valuation is nearly double that of Britain’s HSBC and Switzerland’s Roche, each worth a little over $340 billion, highlighting how scarce its technology and earnings power have become.
Sentiment Indicators
The ranking, based on the latest available market data from StockAnalysis and national exchanges, also shows how Europe’s corporate hierarchy is still dominated by old economy sectors. Banks are the No. 1 company in 15 countries, and finance rises to 18 if insurers and asset managers are included, while energy and utilities lead in 10 more. Together, finance and energy account for 28 of the 42 national champions in the list.
ASML’s dominance also comes as Europe’s previous top company, Novo Nordisk, has lost more than 70% of its peak value. The Danish drugmaker, which was worth more than $650 billion in 2024 on the back of Ozempic and Wegovy, is now valued at about $168.6 billion as Eli Lilly gains ground in the obesity market.
For investors, the message is that Europe’s most valuable company is not a bank or pharma giant but a critical supplier to the AI trade. ASML has reported €8.8 billion in first-quarter sales and €9.3 billion in second-quarter sales this year, while lifting its 2026 revenue outlook to €43 billion-€45 billion with gross margin guidance of 54% to 56%.
The stock has also stayed well above its 200-day moving average, a sign of the long-term uptrend remains intact even after recent pullbacks. ASML closed at 1,780.34 euros on Oct. 9, below the recent peak near 1,987 euros but still far above its 200-day average of about 1,559 euros.
The next catalyst is earnings and management commentary on chip demand, pricing and China exposure. Any sign that ASML’s order book or AI-linked spending is slowing would matter not just for the stock, but for the wider European market’s lone global-scale tech champion.
| Entity | Gains | Losses |
|---|---|---|
| ASML | ▲Europe’s top market cap | ▼Banks and pharma peers |
| AI chipmakers | ▲Access to critical tools | ▼Buyers facing higher costs |
| HSBC/Roche | ▲Stability, but not leadership | ▼Lost top-tier valuation spot |
| Novo Nordisk | ▲Still Denmark’s leader | ▼Peak-value momentum |
